PCVX Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals has a net margin of -- compared to Vaxcyte's net margin of -57.51%. Vaxcyte's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Vaxcyte has a consensus price target of $128.44, signalling upside risk potential of 281.25%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 23.75%. Given that Vaxcyte has higher upside potential than Madrigal Pharmaceuticals, analysts believe Vaxcyte is more attractive than Madrigal Pharmaceuticals.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Vaxcyte's net income of -$137.1M is lower than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Vaxcyte's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Mind Medicine has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat Mind Medicine's return on equity of --.

Vaxcyte has a consensus price target of $128.44, signalling upside risk potential of 281.25%. On the other hand Mind Medicine has an analysts' consensus of $24.50 which suggests that it could grow by 310.39%. Given that Mind Medicine has higher upside potential than Vaxcyte, analysts believe Mind Medicine is more attractive than Vaxcyte.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mind Medicine has a beta of 2.387, suggesting its more volatile than the S&P 500 by 138.658%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mind Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Mind Medicine pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Mind Medicine quarterly revenues of --. Vaxcyte's net income of -$137.1M is lower than Mind Medicine's net income of -$34.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while Mind Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for Mind Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Vaxcyte's net margin of -117.16%. Vaxcyte's return on equity of -- beat Moderna's return on equity of -29.09%.

Vaxcyte has a consensus price target of $128.44, signalling upside risk potential of 281.25%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 92.79%. Given that Vaxcyte has higher upside potential than Moderna, analysts believe Vaxcyte is more attractive than Moderna.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Moderna quarterly revenues of $956M. Vaxcyte's net income of -$137.1M is higher than Moderna's net income of -$1.1B. Notably, Vaxcyte's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 3.36x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Vaxcyte's net margin of 2.31%. Vaxcyte's return on equity of -- beat Pfizer's return on equity of 8.91%.

Vaxcyte has a consensus price target of $128.44, signalling upside risk potential of 281.25%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 26.55%. Given that Vaxcyte has higher upside potential than Pfizer, analysts believe Vaxcyte is more attractive than Pfizer.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.84% to investors and pays a quarterly dividend of $0.43 per share. Vaxcyte pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Vaxcyte's net income of -$137.1M is lower than Pfizer's net income of $410M. Notably, Vaxcyte's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 2.21x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.